» Articles » PMID: 21274650

Racial Differences in Well-being and Cancer Concerns in Prostate Cancer Patients

Overview
Journal J Cancer Surviv
Specialty Oncology
Date 2011 Jan 29
PMID 21274650
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background: We analyzed the racial differences in physical well-being, social/family well-being, functional well-being, emotional well-being, and prostate cancer specific worry among men with clinically localized prostate cancer.

Methods: In this prospective cohort study, we recruited 121 Caucasian and 77 African American men with newly diagnosed prostate cancer. Participants completed the Functional Assessment of Cancer Therapy-Prostate (FACT-P) instrument at baseline and at 3, 6, 12 and 24 months follow-up. To determine the between and within group differences on all functional measures (physical well-being, social/family well-being, functional well-being, emotional well-being, and prostate cancer specific concerns), we used repeated measures ANOVA.

Results: Except for education, income and hospital type, the two racial groups had comparable socio-demographic and clinical attributes. At 3 months post-treatment, both groups experienced a decline in physical well-being and increase in prostate cancer specific concerns. Baseline values of these measures were not recovered by 24-month follow-up. In particular, lack of energy was the most prominent contributor to declining physical well-being. The ability to have and maintain an erection was the most severe prostate cancer specific concern. Lack of energy and concern regarding erection ability varied between the two groups over the follow-up period.

Conclusions: Our findings provide an insight into not only the overall racial variation in physical health and prostate cancer specific concern, but also the temporal differences in these measures that can occur over a 24-month follow-up. This has important implications for effective management of localized prostate cancer patients from different racial groups and merits further research.

Citing Articles

Quality of life assessment among ethnically diverse Black prostate cancer survivors: a constructivist grounded theory approach.

Ogunsanya M, Kaninjing E, Ellis T, Bamidele O, Morton D, McIntosh A J Cancer Surviv. 2024; .

PMID: 38805150 DOI: 10.1007/s11764-024-01619-x.


Quality of Life Assessment Among Ethnically Diverse Black Prostate Cancer Survivors: A Constructivist Grounded Theory Approach.

Ogunsanya M, Kaninjing E, Ellis T, Bamidele O, Morton D, McIntosh A Res Sq. 2024; .

PMID: 38464107 PMC: 10925397. DOI: 10.21203/rs.3.rs-3941497/v1.


Quality of life in the year after new diagnosis with advanced prostate cancer for Black and White individuals living in the US.

Rencsok E, Slopen N, Autio K, Morgans A, McSwain L, Barata P Qual Life Res. 2023; 32(11):3209-3221.

PMID: 37410340 PMC: 10711502. DOI: 10.1007/s11136-023-03468-0.


African-American survivors of prostate cancer: a meta-synthesis of qualitative studies.

Okoro F, Song L, Auten B, Whitaker-Brown C, Cornelius J J Cancer Surviv. 2020; 15(1):40-53.

PMID: 32666419 PMC: 7855211. DOI: 10.1007/s11764-020-00909-4.


Religious Coping and Quality of Life Among Black and White Men With Prostate Cancer.

Bruce M, Bowie J, Barge H, Beech B, LaVeist T, Howard D Cancer Control. 2020; 27(3):1073274820936288.

PMID: 32638611 PMC: 7346696. DOI: 10.1177/1073274820936288.


References
1.
Harlan L, Brawley O, Pommerenke F, Wali P, Kramer B . Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol. 1995; 13(1):93-100. DOI: 10.1200/JCO.1995.13.1.93. View

2.
Engels J, Diehr P . Imputation of missing longitudinal data: a comparison of methods. J Clin Epidemiol. 2003; 56(10):968-76. DOI: 10.1016/s0895-4356(03)00170-7. View

3.
Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta K . Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology. 1998; 50(6):920-8. DOI: 10.1016/S0090-4295(97)00459-7. View

4.
Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

5.
Pettaway C, Troncoso P, Ramirez E, Johnston D, Steelhammer L, Babaian R . Prostate specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens. J Urol. 1998; 160(2):437-42. View